Bristol Myers Squibb
Search results
1 day ago · BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing. For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that ...
2 days ago · Mon, 30 Sept 2024, 1:43 pm 2-min read. (Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene. U.S. District Judge Jesse Furman in Manhattan said UMB Bank was never ...
2 days ago · REUTERS/Brian Snyder/File Photo. (Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval ...
1 day ago · Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of Celgene shareholders. The lawsuit alleged that Bristol Myers delayed drug approvals to avoid contingent value right (CVR) payments from its 2019 Celgene acquisition. The case was dismissed due to UMB’s lack of standing as a "properly appointed trustee."
19 hours ago · Bernie Pazanowski. Bristol-Myers Squibb Co. defeateda $6.4 billion lawsuit against it related to contingent value rights it issued when it purchased Celgene Corp., a federal court said. But the reprieve may be short lived, because Judge Jesse M. Furman’s dismissal was without prejudice, which means that the suit can be refiled.
3 days ago · Bristol-Myers Squibb reveals its new leadership after acquiring Celgene for $74 billion. The deal will create a cancer powerhouse, but also involves some changes and departures in the R&D and commercial divisions.
4 days ago · Celgene's Revlimid was already a blockbuster when BMY acquired it, and it has since increased its sales. Revlimid is used to treat multiple myeloma and certain types of lymphoma, among other ...
